Security key
00166B105
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q3 2023 13F Holders as of 30 Sep 2023
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 33,283,050
- Total 13F value
- $159,762,120
- Share change
- -934,165
- Put/Call ratio
- 6.5%
- SEC-reported price per share
- $4.80
- Number of holders
- 75
- Value change
- -$6,348,070
- Number of buys
- 35
- Number of sells
- 31
- Shares outstanding
- 133,751,136
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2023
Institutions
75
Top holders
10
ALXO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2023
Previous quarter: Q2 2023
ALX ONCOLOGY HOLDINGS INC SEC filings
ALX ONCOLOGY HOLDINGS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00166B105
Recent filing periods:
Ownership snapshot
Top reported holders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
venBio Partners LLC
Disclosed value leader
venBio Partners LLC
Comparable rows
15/15
Latest evidence
30 Jun 2023
13F
Lead comparable stake: 7.3%
Showing 1-6 of 15 holder rows.
Quick read
venBio Partners LLC leads the comparable SEC ownership view at 7.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens venBio Partners LLC's linked filing trail.
Comparable ownership
Top 5
venBio Partners LLC
7.3%
FMR LLC
4.6%
Vivo Capital, LLC
3.2%
ORBIMED ADVISORS LLC
2.1%
BlackRock Finance, Inc.
1.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| venBio Partners LLC |
13F
Company
|
7.3%
|
$72,846,437
9,699,925 shares
|
— | 30 Jun 2023 |
| FMR LLC |
13F
Company
|
4.6%
|
$46,040,348
6,130,539 shares
|
— | 30 Jun 2023 |
| Vivo Capital, LLC |
13F
Company
|
3.2%
|
$31,692,560
4,220,048 shares
|
— | 30 Jun 2023 |
| ORBIMED ADVISORS LLC |
13F
Company
|
2.1%
|
$21,561,210
2,871,000 shares
|
— | 30 Jun 2023 |
| BlackRock Finance, Inc. |
13F
Company
|
1.3%
|
$13,433,589
1,788,760 shares
|
— | 30 Jun 2023 |
| Redmile Group, LLC |
13F
Company
|
0.96%
|
$9,637,500
1,283,289 shares
|
— | 30 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
75
Shares
33,283,050
Rows available
75
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
74
Q3 2023 holders
75
Holder diff
1
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 value | Q3 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend